Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for "NESINA®" (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare.
"We are pleased Takeda has received approval for these additional combination therapies for NESINA in Japan," said June Almenoff, MD, Ph.D., president and chief medical officer of Furiex. "These approvals broaden the indications for combination therapies using NESINA."
Under Furiex's agreement with Takeda, these two approvals do not trigger a milestone payment to Furiex. However, Furiex is entitled to receive royalty payments on sales of NESINA resulting from these approvals.
Early RSV vaccination in pregnancy provides best protection for newborns